Affordable Access

deepdyve-link
Publisher Website

Drug management in acute kidney disease - Report of the ADQI XVI meeting.

Authors
  • Ostermann, M1
  • Chawla, L S2
  • Forni, L G3
  • Kane-Gill, S L4
  • Kellum, J A5
  • Koyner, J6
  • Murray, P T7
  • Ronco, C8
  • Goldstein, S L9
  • 1 King's College London, Guy's & St Thomas' NHS Foundation Hospital, Department of Intensive Care, London, UK.
  • 2 Veterans Affairs Medical Center, Department of Medicine, Washington, DC, USA.
  • 3 Royal Surrey County Hospital NHS Foundation Trust, Intensive Care Unit, Guildford, UK.
  • 4 University of Pittsburgh School of Pharmacy, Pittsburgh, USA.
  • 5 Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh, USA.
  • 6 Department of Medicine, University of Chicago, Chicago, USA.
  • 7 UCD School of Medicine, Health Sciences Centre, University College Dublin, Dublin, Ireland. , (Ireland)
  • 8 Department of Nephrology, Dialysis and Transplantation, San Bortolo Hospital, International Renal Research Institute of Vicenza, Vicenza, Italy. , (Italy)
  • 9 Cincinnati Children's Hospital Medical Center, Division of Nephrology and Hypertension, Cincinnati, USA.
Type
Published Article
Journal
British Journal of Clinical Pharmacology
Publisher
Wiley (Blackwell Publishing)
Publication Date
Oct 11, 2017
Identifiers
DOI: 10.1111/bcp.13449
PMID: 29023830
Source
Medline
Keywords
License
Unknown

Abstract

Drug management during different phases of AKD requires an individualised approach and frequent re-assessment. More research is needed to avoid drug associated harm and therapeutic failure.

Report this publication

Statistics

Seen <100 times